Syneos Health Stock Price, News & Analysis

Syneos Health (Nasdaq:SYNH) will release its second quarter 2021 financial results on August 9, 2021, before the earnings call at 8:00 a.m. ET. The earnings call will be accessible via a live webcast on the company's Investor Relations website. Participants can register in advance to join the call by phone, receiving a confirmation email with details on how to connect. A replay of the webcast will be available after 1:00 p.m. on the same day. This event marks an important opportunity for investors to gather insights on the company's performance.

Syneos Health (Nasdaq:SYNH) has launched a Decentralized Clinical Trials Site Advocacy Group to enhance its Decentralized Solutions, following the recent acquisition of Illingworth Research Group. This initiative seeks to engage with stakeholders and leverage insights to improve decentralized protocol design and patient engagement in clinical trials. The Group aims to streamline operations and reduce patient burdens by incorporating innovative technologies like mobile research and telemedicine. The move is part of Syneos Health's ongoing commitment to accelerate therapy delivery.

Syneos Health (Nasdaq:SYNH) announced the appointment of Dr. David S. Wilkes to its Board of Directors, enhancing leadership with his extensive expertise in pulmonary disease and critical care medicine. Dr. Wilkes, Dean at the University of Virginia School of Medicine, brings a robust academic and entrepreneurial background. The announcement follows the resignation of John Maldonado and Josh Nelson from the Board, which now consists of 10 directors, nine being independent. This transition is aimed at strengthening the Board's composition to better impact patient lives and address healthcare disparities.

Syneos Health (Nasdaq:SYNH) has launched the Patient Voice Consortium, a cross-functional hub aimed at integrating patient perspectives into the product lifecycle. This initiative responds to increased recognition of the 'patient voice' in product development, driven by advocacy and regulatory efforts like the FDA's Patient-Focused Drug Development initiative. The Consortium combines expertise in various fields, including behavioral science and health policy, to enhance patient outcomes and address disparities in healthcare access. This initiative is part of Syneos Health's commitment to innovation and diversity.

Syneos Health, Inc. (Nasdaq: SYNH) announced the pricing of a secondary offering by affiliates of Thomas H. Lee Partners and Advent International of 10,851,676 shares of common stock. Syneos is not selling any shares and will not receive proceeds from the offering, which closes on June 7, 2021. Additionally, the company will repurchase 500,000 shares at the offering price from the selling stockholders, subject to customary conditions. BofA Securities acts as the sole underwriter. This offering is part of Syneos' ongoing capital management strategy.

Syneos Health (Nasdaq: SYNH) has announced a secondary offering of 10,851,676 shares initiated by affiliates of Thomas H. Lee Partners and Advent International. The company is not selling any shares and will not receive proceeds from this transaction. Concurrently, Syneos Health will repurchase 500,000 shares from the Selling Stockholders at the offering price minus commissions.

BofA Securities is the sole underwriter for this offering, which is set to be executed under a previously filed SEC registration statement.

Syneos Health (Nasdaq: SYNH) announced the pricing of an underwritten secondary offering by affiliates of Thomas H. Lee Partners and Advent International. A total of 7,000,000 shares of common stock are being offered, with an additional 1,050,000 shares available to the underwriter. The offering closes on May 6, 2021. Syneos Health is not selling shares and will not receive proceeds from the offering. Additionally, the company will repurchase 400,000 shares from the selling stockholders at the offering price, contingent on the offering's closing.

Syneos Health (Nasdaq: SYNH) announced a secondary offering of 7,000,000 shares by affiliates of Thomas H. Lee Partners and Advent International. The underwriter, B of A Securities, has an option to purchase an additional 1,050,000 shares. Syneos will repurchase 400,000 shares from the Selling Stockholders at the offering price. The offering proceeds will not benefit Syneos, as they are only selling shares held by stockholders. The share repurchase is contingent upon the offering’s closing. Important risks include reliance on key personnel and potential market fluctuations.